Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
CMAB vs IMAB in Metastatic Prostate Cancer
- Conditions
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00255268
- Locations
- 🇲🇽
Research Site, Mexico City, Mexico
Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-06-14
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 62
- Registration Number
- NCT00196846
- Locations
- 🇩🇪
Universitätsfrauenklinik, Rostock Universität, Rostock, Mecklenburg Vorpommern, Germany
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT00165399
- Locations
- 🇺🇸
University of Massachusetts Memorial Medical Center-University Campus, Worcester, Massachusetts, United States
🇺🇸Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 180
- Registration Number
- NCT00002889
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 2028
- Registration Number
- NCT00002597
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 361
- Registration Number
- NCT00002633
- Locations
- 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 983
- Registration Number
- NCT00004124
- Locations
- 🇺🇸
Cancer Care Center at Advocate Lutheran Hospital, Park Ridge, Illinois, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 1386
- Registration Number
- NCT00003653
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2000-02-21
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 159
- Registration Number
- NCT00004635
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Wayne State University Hutzel Hospital, Detroit, Michigan, United States
🇺🇸University of Washington, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.